EFFECTS OF CHROMIUM SUPPLEMENTATION ON SERUM HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS IN MEN TAKING BETA-BLOCKERS - A RANDOMIZED, CONTROLLED TRIAL

被引:63
作者
ROEBACK, JR
HLA, KM
CHAMBLESS, LE
FLETCHER, RH
机构
[1] VET AFFAIRS MED CTR, DURHAM, NC USA
[2] UNIV N CAROLINA, DEPT BIOSTAT, COLLABORAT STUDIES COORDINATING CTR, CHAPEL HILL, NC 27514 USA
[3] DUKE UNIV, MED CTR, DURHAM, NC 27710 USA
关键词
D O I
10.7326/0003-4819-115-12-917
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the efficacy of glucose tolerance factor (GTF)-chromium for increasing serum levels of high-density lipoprotein (HDL) cholesterol in patients taking beta-blockers. Design: Randomized, double-blind, placebo-controlled trial. Setting: Mixed primary and referral-based outpatient clinic at a university-affiliated VA Medical Center. Patients: Referred sample of 72 men receiving beta-blockers, mainly for hypertension. Sixty-three patients (88%) completed the study. Interventions: Current medications, including beta-blockers, were continued. During the 8-week treatment phase, patients in the chromium group received a total daily dose of 600-mu-g of biologically active chromium divided into three equal doses; control patients received a placebo of identical appearance and taste. Measurements: Serum levels of total cholesterol and HDL cholesterol were measured. Main Results: Mean baseline levels of HDL and total cholesterol (+/- SD) were 0.93 +/- 0.28 mmol/L and 6.0 +/- 1.0 mmol/L (36 +/- 11.1 mg/dL and 232 +/- 38.5 mg/dL), respectively. The difference between groups in adjusted mean change in HDL cholesterol levels, accounting for baseline HDL cholesterol levels, age, weight change, and baseline total cholesterol levels, was 0. 15 mmol/L (5.8 mg/dL) (P = 0.01) with a 95% Cl showing that the treatment effect was > + 0.04 mmol/L (+ 1.4 mg/dL). Mean total cholesterol, triglycerides and body weight did not change significantly during treatment for either group. Compliance as measured by pill count was 85%, and few side effects were reported. Two months after the end of treatment, the between-group difference in adjusted mean change from baseline to end of post-treatment follow-up was - 0.003 mmol/L (-0.1 mg/dL). Conclusion: Two months of chromium supplementation resulted in a clinically useful increase in HDL cholesterol levels in men taking beta-blockers.
引用
收藏
页码:917 / 924
页数:8
相关论文
共 42 条
[1]   HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, TOTAL CHOLESTEROL SCREENING, AND MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY [J].
ABBOTT, RD ;
WILSON, PWF ;
KANNEL, WB ;
CASTELLI, WP .
ARTERIOSCLEROSIS, 1988, 8 (03) :207-211
[2]   CHROMIUM INTAKE, ABSORPTION AND EXCRETION OF SUBJECTS CONSUMING SELF-SELECTED DIETS [J].
ANDERSON, RA ;
KOZLOVSKY, AS .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1985, 41 (06) :1177-1183
[3]   EFFECTS OF SUPPLEMENTAL CHROMIUM ON PATIENTS WITH SYMPTOMS OF REACTIVE HYPOGLYCEMIA [J].
ANDERSON, RA ;
POLANSKY, MM ;
BRYDEN, NA ;
BHATHENA, SJ ;
CANARY, JJ .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1987, 36 (04) :351-355
[4]   EFFECTS OF CHROMIUM SUPPLEMENTATION ON URINARY CR EXCRETION OF HUMAN-SUBJECTS AND CORRELATION OF CR EXCRETION WITH SELECTED CLINICAL-PARAMETERS [J].
ANDERSON, RA ;
POLANSKY, MM ;
BRYDEN, NA ;
PATTERSON, KY ;
VEILLON, C ;
GLINSMANN, WH .
JOURNAL OF NUTRITION, 1983, 113 (02) :276-281
[5]   CHROMIUM SUPPLEMENTATION OF HUMAN-SUBJECTS - EFFECTS ON GLUCOSE, INSULIN, AND LIPID VARIABLES [J].
ANDERSON, RA ;
POLANSKY, MM ;
BRYDEN, NA ;
ROGINSKI, EE ;
MERTZ, W ;
GLINSMANN, W .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1983, 32 (09) :894-899
[6]  
Borel J. S., 1984, BIOCH ESSENTIAL ULTR, P175
[7]   CHROMIUM INTAKE AND URINARY CHROMIUM EXCRETION OF TRAUMA PATIENTS [J].
BOREL, JS ;
MAJERUS, TC ;
POLANSKY, MM ;
MOSER, PB ;
ANDERSON, RA .
BIOLOGICAL TRACE ELEMENT RESEARCH, 1984, 6 (04) :317-326
[8]   THE UPTAKE AND EXCRETION OF CHROMIUM BY THE ELDERLY [J].
BUNKER, VW ;
LAWSON, MS ;
DELVES, HT ;
CLAYTON, BE .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1984, 39 (05) :797-802
[9]  
DEFLORA S, 1989, ARCH TOXICOL S, V313, P28
[10]  
ELWOOD JC, 1982, J AM COLL NUTR, V1, P263